Villas B. Hoelz
Pinheiral, RJ, Brazil
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Cruzain Inhibitors for Chagas Disease: Anticorrelated Optimisation Landscapes and the Multiparametric Path to Clinical Candidates.
Journal: Chemical biology & drug design
Published: February 20, 2026
Anti-Trypanosoma cruzi Activity, Mutagenicity, Hepatocytotoxicity and Nitroreductase Enzyme Evaluation of 3-Nitrotriazole, 2-Nitroimidazole and Triazole Derivatives.
Journal: Molecules (Basel, Switzerland)
Published: September 22, 2023
Study of the dynamic behavior of the cruzain enzyme in free and complexed forms with competitive and noncovalent benzimidazole inhibitors.
Journal: Journal of biomolecular structure & dynamics
Published: April 27, 2022
(Phenylamino)pyrimidine-1,2,3-triazole derivatives as analogs of imatinib: searching for novel compounds against chronic myeloid leukemia.
Journal: Beilstein journal of organic chemistry
Published: June 08, 2021
Pyrroles as Privileged Scaffolds in the Search for New Potential HIV Inhibitors.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: May 06, 2021
The Medicinal Chemistry of 3-nitro-1,2,4-triazoles: Focus on Infectious Diseases.
Journal: Current topics in medicinal chemistry
Published: March 31, 2021
In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19.
Journal: The Journal of antimicrobial chemotherapy
Published: October 10, 2020
P2X7 receptor inhibition by 2-amino-3-aryl-1,4-naphthoquinones.
Journal: Bioorganic chemistry
Published: March 10, 2020
Yellow fever virus is susceptible to sofosbuvir both in vitro and in vivo.
Journal: PLoS neglected tropical diseases
Published: March 25, 2018
New 1,2,3-triazole-based analogues of benznidazole for use against Trypanosoma cruzi infection: In vitro and in vivo evaluations.
Journal: Chemical biology & drug design
Published: February 20, 2018
Corrigendum: The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication.
Journal: Scientific reports
Published: April 25, 2017
The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication.
Journal: Scientific reports
Published: October 18, 2016
Showing 1-12 of 12
Last Updated: 09/26/2026